Asset Details
Do you wish to reserve the book?
Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis
Do you wish to request the book?
Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis
2017
Overview
Among participants with eosinophilic granulomatosis with polyangiitis, 32% had remission at weeks 36 and 48 when treated with mepolizumab, an anti–interleukin-5 monoclonal antibody, as compared with 3% of the participants in the placebo group.
Eosinophilic granulomatosis with polyangiitis (formerly known as the Churg–Strauss syndrome) is characterized by asthma, sinusitis, pulmonary infiltrates, neuropathy, and eosinophilic vasculitis of one or more end-organs.
1
–
4
Eosinophils are thought to induce pathogenic effects in patients with eosinophilic granulomatosis with polyangiitis by means of tissue and vascular infiltration and inflammation through a variety of mediators.
5
,
6
Although systemic glucocorticoids form the cornerstone of treatment for eosinophilic granulomatosis with polyangiitis,
7
–
9
most patients remain dependent on glucocorticoid therapy, and relapses are common.
10
–
13
Furthermore, some patients do not have a sufficient response to glucocorticoids. Because recurrent relapses place the patient at . . .
Publisher
Massachusetts Medical Society
Subject
/ Antibodies, Monoclonal, Humanized - adverse effects
/ Antibodies, Monoclonal, Humanized - therapeutic use
/ Asthma
/ Churg-Strauss Syndrome - drug therapy
/ Churg-Strauss Syndrome - immunology
/ Female
/ Glucocorticoids - therapeutic use
/ Humans
/ Immunologic Factors - adverse effects
/ Immunologic Factors - therapeutic use
/ Injections, Subcutaneous - adverse effects
/ Male
/ Placebos
